Title |
The clinical application of linagliptin in Asians
|
---|---|
Published in |
Therapeutics and Clinical Risk Management, September 2015
|
DOI | 10.2147/tcrm.s64402 |
Pubmed ID | |
Authors |
Chu-qing Cao, Yu-fei Xiang, Zhi-guang Zhou |
Abstract |
Asia has a growing diabetic population. Linagliptin, a member of dipeptidyl peptidase-4 inhibitor class, is unique in its nonlinear pharmacokinetics with the characteristics of rapid attainment of steady state, little accumulation, predominantly nonrenal route of elimination, prolonged terminal half-life, and sustained inhibition of dipeptidyl peptidase-4 enzyme. No clinically relevant difference in pharmacokinetics was observed between Asians and non-Asians. The management of type 2 diabetes is increasingly challenging with the progression of disease, especially with the requirements of minimal hypoglycemia, weight gain, fluid retention, and other adverse effects. Linagliptin was efficacious and well-tolerated in Asian type 2 diabetes patients with or without renal or hepatic dysfunctions, comparable to that in Caucasians. This review will focus on the usage of linagliptin in clinical studies in Asians. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 22 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 23% |
Other | 3 | 14% |
Student > Postgraduate | 3 | 14% |
Librarian | 2 | 9% |
Researcher | 2 | 9% |
Other | 2 | 9% |
Unknown | 5 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 45% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 18% |
Computer Science | 1 | 5% |
Business, Management and Accounting | 1 | 5% |
Unknown | 6 | 27% |